| Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis F Ceban, S Ling, LMW Lui, Y Lee, H Gill, KM Teopiz, NB Rodrigues, ... Brain, behavior, and immunity 101, 93-135, 2022 | 993 | 2022 |
| Government response moderates the mental health impact of COVID-19: a systematic review and meta-analysis of depression outcomes across countries Y Lee, LMW Lui, D Chen-Li, Y Liao, RB Mansur, E Brietzke, JD Rosenblat, ... Journal of affective disorders 290, 364-377, 2021 | 205 | 2021 |
| The effect of intravenous, intranasal, and oral ketamine in mood disorders: a meta-analysis RS McIntyre, IP Carvalho, LMW Lui, A Majeed, PS Masand, H Gill, ... Journal of affective disorders 276, 576-584, 2020 | 151 | 2020 |
| Antidepressant medications and weight change: a narrative review H Gill, B Gill, S El‐Halabi, D Chen‐Li, O Lipsitz, JD Rosenblat, ... Obesity 28 (11), 2064-2072, 2020 | 94 | 2020 |
| The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: a systematic review and … J Xiong, O Lipsitz, D Chen-Li, JD Rosenblat, NB Rodrigues, I Carvalho, ... Journal of psychiatric research 134, 57-68, 2021 | 91 | 2021 |
| Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis Y Alnefeesi, D Chen-Li, E Krane, MY Jawad, NB Rodrigues, F Ceban, ... Journal of psychiatric research 151, 693-709, 2022 | 90 | 2022 |
| The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar … RS McIntyre, NB Rodrigues, Y Lee, O Lipsitz, M Subramaniapillai, H Gill, ... Journal of Affective Disorders 274, 903-910, 2020 | 78 | 2020 |
| Molecular mechanisms of psilocybin and implications for the treatment of depression S Ling, F Ceban, LMW Lui, Y Lee, KM Teopiz, NB Rodrigues, O Lipsitz, ... CNS drugs 36 (1), 17-30, 2022 | 69 | 2022 |
| The effects of ketamine on cognition in treatment-resistant depression: a systematic review and priority avenues for future research H Gill, B Gill, NB Rodrigues, O Lipsitz, JD Rosenblat, S El-Halabi, F Nasri, ... Neuroscience & Biobehavioral Reviews 120, 78-85, 2021 | 60 | 2021 |
| Registered clinical trials investigating treatment of long COVID: a scoping review and recommendations for research F Ceban, A Leber, MY Jawad, M Yu, LMW Lui, M Subramaniapillai, ... Infectious Diseases 54 (7), 467-477, 2022 | 59 | 2022 |
| The effectiveness of ketamine on anxiety, irritability, and agitation: implications for treating mixed features in adults with major depressive or bipolar disorder RS McIntyre, O Lipsitz, NB Rodrigues, Y Lee, DS Cha, M Vinberg, K Lin, ... Bipolar disorders 22 (8), 831-840, 2020 | 49 | 2020 |
| Prevention and management of common adverse effects of ketamine and esketamine in patients with mood disorders F Ceban, JD Rosenblat, K Kratiuk, Y Lee, NB Rodrigues, H Gill, ... CNS drugs 35 (9), 925-934, 2021 | 47 | 2021 |
| Social isolation, loneliness and generalized anxiety: implications and associations during the COVID-19 quarantine L Wilkialis, NB Rodrigues, DS Cha, A Siegel, A Majeed, LMW Lui, ... Brain sciences 11 (12), 1620, 2021 | 42 | 2021 |
| Antisuicidal and antidepressant effects of ketamine and esketamine in patients with baseline suicidality: A systematic review AN Siegel, JD Di Vincenzo, E Brietzke, H Gill, NB Rodrigues, LMW Lui, ... Journal of psychiatric research 137, 426-436, 2021 | 40 | 2021 |
| Extracellular vesicle biomarkers reveal inhibition of neuroinflammation by infliximab in association with antidepressant response in adults with bipolar depression RB Mansur, F Delgado-Peraza, M Subramaniapillai, Y Lee, M Iacobucci, ... Cells 9 (4), 895, 2020 | 40 | 2020 |
| Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of Excellence NB Rodrigues, RS McIntyre, O Lipsitz, DS Cha, Y Lee, H Gill, A Majeed, ... Journal of affective disorders 276, 570-575, 2020 | 39 | 2020 |
| Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: a systematic review J Ng, JD Rosenblat, LMW Lui, KM Teopiz, Y Lee, O Lipsitz, RB Mansur, ... Journal of affective disorders 293, 285-294, 2021 | 37 | 2021 |
| The emerging role of psilocybin and MDMA in the treatment of mental illness H Gill, B Gill, D Chen-Li, S El-Halabi, NB Rodrigues, DS Cha, O Lipsitz, ... Expert Review of Neurotherapeutics 20 (12), 1263-1273, 2020 | 37 | 2020 |
| The association between adverse childhood experiences and inflammation in patients with major depressive disorder: a systematic review H Gill, S El-Halabi, A Majeed, B Gill, LMW Lui, RB Mansur, O Lipsitz, ... Journal of affective disorders 272, 1-7, 2020 | 37 | 2020 |
| The effectiveness, safety and tolerability of ketamine for depression in adolescents and older adults: a systematic review JD Di Vincenzo, A Siegel, O Lipsitz, R Ho, KM Teopiz, J Ng, LMW Lui, ... Journal of psychiatric research 137, 232-241, 2021 | 35 | 2021 |
